- Home
- ASND vs PEN Comparison
ASND vs PEN Comparison
Compare ASND & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | PEN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 14.0B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASND | PEN |
|---|---|---|
| Price | $232.30 | $343.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | $277.13 | ★ $357.33 |
| AVG Volume (30 Days) | 694.9K | ★ 791.3K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | N/A | ★ 4.52 |
| Revenue | N/A | ★ $1,403,665,000.00 |
| Revenue This Year | $98.99 | $13.92 |
| Revenue Next Year | $41.45 | $13.82 |
| P/E Ratio | ★ N/A | $75.65 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $124.06 | $221.26 |
| 52 Week High | $242.00 | $362.41 |
Technical Indicators
Market Signals| Indicator | ASND | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 55.92 |
| Support Level | $190.49 | $337.63 |
| Resistance Level | $242.00 | $362.41 |
| Average True Range (ATR) | 9.59 | 2.18 |
| MACD | 0.44 | -1.00 |
| Stochastic Oscillator | 81.29 | 89.60 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.